The year's new drugs & biologics - 2009

Drug News and Perspectives

Volumn 23, Issue 1, 2010, Pages 7-36

  Graul, Ann I ^a   Sorbera, Lisa ^a   Pina, Patricia ^a   Tell, Montse ^a   Cruces, Elisabet ^a   Rosa, Esmeralda ^a   Stringer, Mark ^a   Castañer, Rosa ^a   Revel, Laura ^a  

^a Editorial Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; APLENZIN; ARMODAFINIL; ARZERRA; ASENAPINE; CANAKINUMAB; CATUMAXOMAB; DEGARELIX; DENOSUMAB; DEXAMETHASONE; EFIENT; ELLA ONE; EMBEDA; ESLICARBAZEPINE ACETATE; FEBUXOSTAT; FERUMOXYTOL; FIRMAGON; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; FOSPROPOFOL; GOLIMUMAB; GUANFACINE; INTUNIV; KAPIDEX; LIRAGLUTIDE; MORPHINE SULFATE; MULTAQ; NALTREXONE; NICOTINIC ACID; OFATUMUMAB; OLANZAPINE; OZURDEX; PALIPERIDONE; PAZOPANIB; PHENTOLAMINE MESYLATE; PLERIXAFOR; PRALATREXATE; PRASUGREL; REMITCH; SAMSCA; SAXAGLIPTIN; SYNFLORIX; TELAVANCIN; TOLVAPTAN; TRASTUZUMAB; TWYNSTA; TYVASO; ULORIC; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VALTURNA; ZEBINIX; ZYPADHERA;

ANALGESIA; ANESTHESIA; ATTENTION DEFICIT DISORDER; B CELL LYMPHOMA; BLADDER CANCER; BREAST CANCER; COLORECTAL CANCER; COMMUNITY ACQUIRED PNEUMONIA; CONGESTIVE HEART FAILURE; DEPRESSION; DIGESTIVE SYSTEM CANCER; DRUG APPROVAL; DRUG FORMULATION; DRUG MARKETING; DRUG MECHANISM; DRUG RELEASE; DRUG RESEARCH; DRUG SYNTHESIS; EPILEPSY; FEMALE INFERTILITY; FOLLICULAR LYMPHOMA; GLIOBLASTOMA; HUMAN; KIDNEY POLYCYSTIC DISEASE; LUNG NON SMALL CELL CANCER; LYMPHEDEMA; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NASOPHARYNX CANCER; OBESITY; OSTEOPOROSIS; OVARY CANCER; PLEURA MESOTHELIOMA; PROSTATE CANCER; PSORIASIS; RETINA MACULA DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SCHIZOPHRENIA; SOFT TISSUE SARCOMA; THYROID CANCER; ULCERATIVE COLITIS; UTERINE CERVIX CANCER; WALDENSTROEM MACROGLOBULINEMIA;

BIOLOGICAL PRODUCTS; DRUG APPROVAL; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 77950623162     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2010.23.1.1440373     Document Type: Review

References (25)

1. Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, United States, 2006. Morbidity and Mortality Weekly Report 2009, December 18. Available at http://www.cdc.gov/mmwr/preview/ mmwrhtml/ss5810al. htm (accessed December 21, 2009).
2. Prous Science Integrity® Disease Briefing: Hepatitis B.
3. Prous Science Integrity® Disease Briefing: Influenza.
4. Graul, A.I., Revel, L., Barrionuevo, M. et al. The year's new drugs and biologies, 2008. Drug News Perspect 2009, 22(1): 7-29.
5. Prous Science Integrity® Disease Briefing: Cutaneous T-cell lymphoma.
6. Zheng, C.J., Han, L.Y., Yap, C.W., Xie, B., Chen, YZ. Trends in exploration of therapeutic targets. Drug News Perspect 2005, 18(2): 109-127
7. Scanlon, J.V., Exter, B.P., Steinberg, M., Jarvis, C.I. Ustekinumab: Treatment of adult moderate-to-severe chronic plaque psoriasis. Ann Pharmacother 2009, 43(9): 1456-1465
8. Menter, A. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis 2009, 84(4, Suppl.): 14.
9. Shear, N.H., Prinz, J., Papp, K., Langley, R.G., Gulliver, W.P. Targeting the interleukin-12/23 cytokine family in the treatment of psoriatic disease. J Cutan Med Surg 2008, 12(Suppl. 1): S1-10.
10. Elder, J.T. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun 2009, 10(3): 201-209
11. Nograles, K.E., Brasington, R.D., Bowcock, A.M. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol 2009, 5(2): 83-91.
12. Normand, S., Massonnet, B., Delwail, A. et al. Specific increase in caspase-1 activity and secretion of IL-1 family cytokines: A putative link between mevalonate kinase deficiency and inflammation. Eur Cytokine Netw 2009, 20(3): 101-107
13. Lachmann, H.J., Kone-Paut, I., Kuemmerle-Deschner, J.B. et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009, 360(23): 2416-2425
14. Bryant, C., Fitzgerald, K.A. Molecular mechanisms involved in inflammasome activation. Trends Cell Biol 2009, 19(9): 455-464
15. Sebastian, M., Kuemmel, A., Schmidt, M., Schmittel, A. Catumaxomab: A bispecific tri-functional antibody. Drugs Today (Barc) 2009, 45(8): 589-597
16. Baeuerle, P.A., Reinhardt, C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009, 69(12): 4941-4944
17. Munz, M., Baeuerle, P.A., Gires, O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009, 69(14): 5627-5629
18. Carpenter, G., Red Brewer, M. EpCAM: Another surface-to-nucleus missile. Cancer Cell 2009, 15(3): 165-166
19. Ooi, L.L., Dunstan C.R. CXCL12/CXCR4 axis in tissue targeting and bone destruction in cancer and multiple myeloma. J Bone Miner Res 2009, 04(7): 1147-1149
20. Wu, X., Lee, V.C, Chevalier, E., Hwang, S.T. Chemokine receptors as targets for cancer therapy. Curr Pharm Des 2009, 15(7): 742-757
21. Wagstaff, A.J. Plerixafor: In patients with non-Hodgkin's lymphoma or multiple myeloma. Drugs 2009, 69(3): 319-326
22. Pintiaux, A., Chabbert-Buffet, N., Foidart, J.M. Gynaecological uses of a new class of steroids: The selective progesterone receptor modulators. Gynecol Endocrinol 2009, 25(2): 67-73.
23. Zhi, L. Discovery of structurally diverse nonsteroidal SPRMs based on a screening hit, 1,2-dihydro-2,2,4-trimethyl-6-phenylquinolinone. Curr Top Med Chem 2008, 8(9): 766-780
24. Benagiano, G., Bastianelli, C., Farris, M. Hormonal contraception: State of the an and future perspectives. Minerva Gynecol 2007, 59(3): 241-270
25. Cavalla, D. APT drug R&D: The right active ingredient in the right presentation for the right therapeutic use. Nat Rev Drug Disc 2009 8(11): 849.